Related Experiment Videos
'One-visit' therapy for pelvic inflammatory disease
Abstract:
Acute pelvic inflammatory disease is a very common gynaecological disorder, and more often than not it is caused by a mixed infection of aerobic and anaerobic organisms. Routine bacteriological investigation is consequently of little practical value in determining the therapeutic approach. In an open comparative trial, 60 patients were divided into two treatment groups of 30 patients each. Both groups received a combination of penicillins, probenecid, a sulphonamide and an imidazole derivative active against protozoa and anaerobes. Both regimens resulted in virtually the same therapeutic response in patients hospitalized for 6 days. The regimen consisting of ornidazole (as opposed to metronidazole) and the ultralong-acting sulphonamide, sulphadoxine (as opposed to sulphadimidine), can be given in a once-only administration, thereby greatly reducing the possibility of non-compliance in patients treated, as is customary, on an outpatient basis.
Insights
This study compared two treatment regimens for pelvic inflammatory disease (PID). Ornidazole and sulphadoxine offered a convenient once-only dose, improving patient compliance for this common gynecological infection.
Area of Science:
- Gynecology
- Infectious Diseases
- Pharmacology
Background:
- Acute pelvic inflammatory disease (PID) is a common gynecological disorder.
- Often caused by mixed aerobic and anaerobic infections, making routine bacteriological investigation challenging.
- Current therapeutic approaches may face challenges with patient compliance, especially in outpatient settings.
Purpose of the Study:
- To compare the therapeutic efficacy of two different treatment regimens for acute PID.
- To evaluate the convenience and compliance benefits of a once-only administration regimen.
- To assess the effectiveness of ornidazole and sulphadoxine compared to metronidazole and sulphadimidine in PID treatment.
Main Methods:
- An open comparative trial involving 60 patients with acute PID.
- Patients were divided into two groups of 30.
- Both groups received a combination of penicillins, probenecid, a sulphonamide, and an imidazole derivative, with variations in the specific drugs used (ornidazole/sulphadoxine vs. metronidazole/sulphadimidine).
Main Results:
- Both treatment regimens demonstrated virtually the same therapeutic response in hospitalized patients.
- The regimen including ornidazole and the ultralong-acting sulphonamide, sulphadoxine, allowed for a once-only administration.
- This once-only administration significantly reduces the potential for non-compliance in patients, particularly those treated on an outpatient basis.
Conclusions:
- A once-only administration regimen of ornidazole and sulphadoxine is as effective as other combination therapies for acute PID.
- This simplified dosing regimen offers a significant advantage in improving patient compliance for PID treatment.
- The findings support the use of ornidazole and sulphadoxine for a more convenient and potentially more effective outpatient management of acute pelvic inflammatory disease.